← All trials
NCT05603884
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2022
- Primary completion
- Dec 31, 2024
- Completion date
- Jun 30, 2025
- First posted
- Nov 3, 2022
- Last posted
- Nov 3, 2022
- Enrollment
- 66
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Xiamen UniversityLead sponsor
- Chipscreen Biosciences, Ltd.Collaborator
- Fujian Medical UniversityCollaborator
- Xiamen UniversityOverall official - principal investigator
- Huizhou People's Central HospitalCollaborator
- Zhangzhou Municipal Hospital of Fujian ProvinceCollaborator
- Shijiazhuang Pharma Group (CSPC)Collaborator
- Fujian Provincial HospitalCollaborator
- Jieyang People's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.